1,000+ Opportunities
Find the right grant
Search federal, foundation, and corporate grants with AI — or browse by agency, topic, and state.
This listing may be outdated. Verify details at the official source before applying.
Find similar grantsNational Institutes of Health (NIH) Director's New Innovator Award Program (DP2 Clinical Trial Optional) is sponsored by National Institutes of Health. This program supports unusually innovative research from new investigators.
Get a weekly digest of new grants like this
A free weekly digest of new foundation and federal funding opportunities as they're added to Granted. Unsubscribe anytime.
Or search similar grants →Extracted from the official opportunity page/RFP to help you evaluate fit faster.
RFA-RM-27-002: NIH Director’s New Innovator Award (DP2 Clinical Trial Optional) Department of Health and Human Services Part 1.
Overview Information Participating Organization(s) National Institutes of Health ( NIH ) Components of Participating Organizations NATIONAL INSTITUTES OF HEALTH ( NIH ) This Notice of Funding Opportunity (NOFO) is developed as a Common Fund initiative through the Office of the NIH Director, Office of Strategic Coordination. All NIH Institutes and Centers participate in Common Fund initiatives.
Funding Opportunity Title NIH Director's New Innovator Award (DP2 Clinical Trial Optional) DP2 NIH Director's New Innovator Awards Check for any recent Notices of NIH Policy Changes that may impact application requirements. Funding Opportunity Number (FON) Companion Funding Opportunity There is no limit to the number of applications an institution may submit. Individuals may submit only one application as PD/PI in response to this NOFO.
Assistance Listing Number(s) Funding Opportunity Purpose The NIH Director's New Innovator Award supports early-stage investigators of exceptional creativity who propose bold and highly innovative research projects with the potential to produce a major impact on broad, important areas relevant to the mission of NIH.
Applications in any area within the biomedical sciences are welcome; topics may involve basic, translational, or clinical research. The NIH Director's New Innovator Award complements other ongoing efforts by NIH and its Institutes and Centers to fund early-stage investigators. The NIH Director's New Innovator Award is a component of the High-Risk, High-Reward Research (HRHR) program of the NIH Common Fund .
Funding Opportunity Goal(s) This listing covers the Common Fund, administered by the Office of Strategic Coordination (OSC) in the NIH Office of the Director which offers assistance awards or supplements to assistance awards. Open Date (Earliest Submission Date) Renewal / Resubmission / Revision (as allowed) AIDS - New/Renewal/Resubmission/Revision, as allowed All applications are due by 5:00 PM local time of applicant organization.
Applicants are encouraged to apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date. No late applications will be accepted for this Notice of Funding Opportunity (NOFO).
Required Application Instructions It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide , except where instructed to do otherwise (in this NOFO or in a Notice from NIH Guide for Grants and Contracts ). Conformance to all requirements (both in the How to Apply - Application Guide and the NOFO) is required and strictly enforced.
Applicants must read and follow all application instructions in the How to Apply - Application Guide as well as any program-specific instructions noted in Section IV. When the program-specific instructions deviate from those in the How to Apply - Application Guide , follow the program-specific instructions. Applications that do not comply with these instructions may be delayed or not accepted for review.
There are several options available to submit your application through Grants. gov to NIH and Department of Health and Human Services partners. You must use one of these submission options to access the application forms for this opportunity.
Use the NIH ASSIST system to prepare, submit and track your application online. Use an institutional system-to-system (S2S) solution to prepare and submit your application to Grants. gov and eRA Commons to track your application.
Check with your institutional officials regarding availability. Use Grants. gov Workspace to prepare and submit your application and eRA Commons to track your application.
Part 1. Overview Information Part 2. Full Text of Announcement Section I.
Notice of Funding Opportunity Description Section II. Award Information Section III. Eligibility Information Section IV.
Application and Submission Information Section V. Application Review Information Section VI. Award Administration Information Section VII.
Agency Contacts Section VIII. Other Information Part 2. Full Text of Announcement Section I.
Notice of Funding Opportunity Description The NIH Director's New Innovator Award addresses two important goals: stimulating bold and highly innovative research and supporting promising Early Stage Investigators, as defined by NIH policy . Early Stage Investigators may have exceptionally innovative research ideas but not the preliminary data required to fare well in the traditional NIH peer review system.
As part of NIH's commitment to increasing opportunities for Early Stage Investigators, it has designed the NIH Director's New Innovator Award to support exceptionally creative Early Stage Investigators who propose bold and highly innovative research projects with the potential for unusually high impact.
This award complements ongoing efforts by the NIH and its Institutes and Centers to fund Early Stage Investigators through R01 grants and other mechanisms. The NIH Director's New Innovator Award is different from traditional NIH grants in several aspects.
It is specifically designed to support unusually creative investigators with bold and highly innovative research ideas at an early stage of their career when they may lack the preliminary data required for a conventional R01 grant application. The emphasis is on innovation and creativity; preliminary data are not required but may be included.
The review process emphasizes the individual's creativity, the innovativeness of the research approaches, and the potential of the project, if successful, to have a significant impact on an important biomedical research problem. Given the highly innovative nature of the research, New Innovator Award recipients are given unusual flexibility to pivot research directions as they see fit to maximize research impact.
Applications are welcome in all research areas broadly relevant to the mission of NIH. Research may be basic, translational, or clinical. The primary requirements are that the research be highly innovative and have the potential for unusually broad impact.
Investigators who were not selected for an award in prior years may submit applications for this competition as long as they meet eligibility requirements (including Early Stage Investigator status) described in this NOFO; however, all applications must be submitted as "new" applications, regardless of any previous submission to the initiative. No reference to any prior application may be included.
Any reference to a prior application may be grounds for administrative withdrawal. NIH program staff will hold a pre-application webinar to explain the program and answer questions about the application and review process. Check the NIH Calendar of Events for more information.
Questions should be sent to NewInnovatorAwards@mail. nih. gov .
More information, FAQs, application guide, contacts for clinical trials, and webinar recording are on the Common Fund website . The NIH Director's New Innovator Award is part of the High-Risk, High-Reward Research (HRHR) program funded through the NIH Common Fund, which supports cross-cutting programs that are expected to have exceptionally high impact.
All Common Fund initiatives invite investigators to develop bold, innovative, and often risky approaches to address problems that may seem intractable or to seize new opportunities that offer the potential for rapid progress. Investigators proposing NIH-defined clinical trials may refer to the Research Methods Resources website for information about developing statistical methods and study designs. See Section VIII.
Other Information for award authorities and regulations. Section II. Award Information Grant: A financial assistance mechanism providing money, property, or both to an eligible entity to carry out an approved project or activity.
Application Types Allowed The OER Glossary and the How to Apply - Application Guide provide details on these application types. Only those application types listed here are allowed for this NOFO. Optional: Accepting applications that either propose or do not propose clinical trial(s).
Need help determining whether you are doing a clinical trial? Funds Available and Anticipated Number of Awards NIH intends to commit approximately $23 million for approximately 30 awards in FY 2027. The number of awards is contingent upon NIH appropriations and the submission of a sufficient number of meritorious applications.
Awards will be for up to $475,000 in Direct Costs per year, plus applicable indirect costs. Project periods will be for five years. NIH grants policies as described in the NIH Grants Policy Statement will apply to the applications submitted and awards made from this NOFO.
Section III.
Eligibility Information Higher Education Institutions - Includes all types Public/State Controlled Institutions of Higher Education Private Institutions of Higher Education Nonprofits Other Than Institutions of Higher Education Nonprofits with 501(c)(3) IRS Status (Other than Institutions of Higher Education) Nonprofits without 501(c)(3) IRS Status (Other than Institutions of Higher Education) For-Profit Organizations (Other than Small Businesses) City or Township Governments Special District Governments Indian/Native American Tribal Governments (Federally Recognized) Indian/Native American Tribal Governments (Other than Federally Recognized) Eligible Agencies of the Federal Government, excluding the NIH Intramural Research Program (IRP) U.S. Territory or Possession Independent School Districts Public Housing Authorities/Indian Housing Authorities Native American Tribal Organizations (other than Federally recognized tribal governments) Faith-based or Community-based Organizations Foreign Organizations/Foreign Collaborations Non-domestic (non-U.S.) Entities (Foreign Organizations) are not eligible to apply.
Non-domestic (non-U.S.) components of U.S. Organizations are not eligible to apply. Foreign components, as defined in the NIH Grants Policy Statement , are allowed. NIH will no longer issue awards (i.e., new, renewal, or non-competing continuation) to domestic or foreign entities that involve foreign subawards/subcontracts.
All NIH-funded research involving foreign subawards/subcontracts must be submitted in response to a NOFO that is specifically designated for funded international collaborations. See NIH Grants Policy Statement 16. 8 Collaborative International Research Awards .
Applications involving foreign subawards/subcontracts submitted in response to this NOFO will be deemed noncompliant and will not be considered for funding.
This policy applies to all monetary international collaborations resulting in foreign subawards/subcontracts, however, it does not preclude unfunded international collaborations or foreign components , funding for foreign consultants, or procurement of unique equipment or supplies from foreign vendors.
Applicant organizations must complete and maintain the following registrations as described in the How to Apply - Application Guide to be eligible to apply for or receive an award. All registrations must be completed prior to the application being submitted. Registration can take 6 weeks or more, so applicants should begin the registration process as soon as possible.
Failure to complete registrations in advance of a due date is not a valid reason for a late submission, please reference NIH Grants Policy Statement Section 2. 3. 9.
2 Electronically Submitted Applications for additional information System for Award Management (SAM) – Applicants must complete and maintain an active registration, which requires renewal at least annually . The renewal process may require as much time as the initial registration.
SAM registration includes the assignment of a Commercial and Government Entity (CAGE) Code for domestic organizations which have not already been assigned a CAGE Code. Foreign organizations must obtain a NATO Commercial and Government Entity (NCAGE) Code (in lieu of a CAGE code) in order to register in SAM. Unique Entity Identifier (UEI)- A UEI is issued as part of the SAM.
gov registration process. The same UEI must be used for all registrations, as well as on the grant application. eRA Commons - Once the unique organization identifier is established, organizations can register with eRA Commons in tandem with completing their Grants.
gov registrations; all registrations must be in place by time of submission. eRA Commons requires organizations to identify at least one Signing Official (SO) and at least one Program Director/Principal Investigator (PD/PI) account in order to submit an application. Grants.
gov – Applicants must have an active SAM registration in order to complete the Grants. gov registration. Program Directors/Principal Investigators (PD(s)/PI(s)) All PD(s)/PI(s) must have an eRA Commons account.
PD(s)/PI(s) should work with their organizational officials to either create a new account or to affiliate their existing account with the applicant organization in eRA Commons. If the PD/PI is also the organizational Signing Official, they must have two distinct eRA Commons accounts, one for each role. Obtaining an eRA Commons account can take up to 2 weeks.
All PD(s)/PI(s) must be registered with ORCID . The personal profile associated with the PD(s)/PI(s) eRA Commons account must be linked to a valid ORCID ID. For more information on linking an ORCID ID to an eRA Commons personal profile see the ORCID topic in our eRA Commons online help .
Eligible Individuals (Program Director/Principal Investigator) Any individual(s) with the skills, knowledge, and resources necessary to carry out the proposed research as the Program Director(s)/Principal Investigator(s) (PD(s)/PI(s)) is invited to work with their organization to develop an application for support. Only single PD/PI applications are allowed. Applications with multiple PD(s)/PI(s) will not be accepted.
There is no limit to the number of applications an institution may submit, but individuals may submit only one application as PD/PI in response to this NOFO. Applicants must meet the definition of an Early Stage Investigator (ESI) at the time of application submission.
An ESI is a PD/PI who has completed their terminal research degree or end of post-graduate clinical training, whichever date is later, within the past 10 years and who has not previously competed successfully as PD/PI for a substantial NIH independent research award.
See the Office of Extramural Research website for a complete list of NIH awards that do not disqualify a PD/PI as a new investigator and for frequently asked questions about the NIH ESI Policy . An extension to the 10-year period may be granted under certain circumstances (e.g., childbirth, family care responsibilities, clinical loan repayment requirements, disability or illness, natural or other disaster, etc.).
It may take several weeks for the review process for the request, so applicants should plan accordingly. Note: If an applicant is not identified as an ESI in the eRA Commons, it may result in the application not being reviewed. Applicants are responsible for reviewing and/or updating their degree information in their eRA Commons account in a timely fashion.
Applicants must hold an independent research position at a domestic (U.S.) institution by September 1, 2027. For this NOFO, an "independent research position" is a position that automatically confers eligibility to the investigator (based on institutional policy) to apply for R01 grants with appropriate institutional commitment of facilities for the conduct of the proposed research.
Investigators still in training or mentored status (such as postdoctoral fellows) are not eligible to apply unless they have a written commitment from the institution stating they will be in an independent faculty position by September 1, 2027. The commitment is certified by the institution's submission of the application.
Applicants may submit or have an NIH R01 or other grant application (including an ESI MIRA R35 application) pending concurrently with their NIH Director's New Innovator Award application, but scientific overlap is not allowed per NIH policy.
If a pending grant becomes active prior to the New Innovator Award, and the grant mechanism is not on the list of smaller NIH grants and awards that maintain ESI status, then the applicant is no longer eligible to receive the New Innovator Award. Award recipients are required to commit at least three person-months (25%) of their research effort each year to activities supported by the New Innovator Award.
This NOFO does not require cost sharing as defined in the NIH Grants Policy Statement NIH Grants Policy Statement Section 1. 2 Definition of Terms. 3.
Additional Information on Eligibility Applicant organizations may submit more than one application, provided that each application is scientifically distinct. The NIH will not accept duplicate or highly overlapping applications under review at the same time, per NIH Grants Policy Statement Section 2. 3.
7. 4 Submission of Resubmission Application . This means that the NIH will not accept: A new (A0) application that is submitted before issuance of the summary statement from the review of an overlapping new (A0) or resubmission (A1) application.
A resubmission (A1) application that is submitted before issuance of the summary statement from the review of the previous new (A0) application. An application that has substantial overlap with another application pending appeal of initial peer review (see NIH Grants Policy Statement 2. 3.
9. 4 Similar, Essentially Identical, or Identical Applications ). Section IV.
Application and Submission Information 1. Requesting an Application Package The application forms package specific to this opportunity must be accessed through ASSIST, Grants. gov Workspace or an institutional system-to-system solution.
Links to apply using ASSIST or Grants. gov Workspace are available in Part 1 of this NOFO. See your administrative office for instructions if you plan to use an institutional system-to-system solution.
2. Content and Form of Application Submission It is critical that applicants follow the instructions in the Research (R) Instructions in the How to Apply - Application Guide except where instructed in this notice of funding opportunity to do otherwise (in this NOFO, in a policy notice , or other notice from NIH Guide for Grants and Contracts ).
Conformance to the requirements in the How to Apply - Application Guide is required and strictly enforced. Applications that are out of compliance with these instructions may be delayed or not accepted for review. All page limitations described in the How to Apply – Application Guide and the Table of Page Limits must be followed.
Instructions for Application Submission The following section supplements the instructions found in the How to Apply – Application Guide and should be used for preparing an application to this NOFO. All instructions in the How to Apply - Application Guide must be followed. Agency Routing Identifier (Field 4b) : Enter science area designations.
Using the list below, designate the two most appropriate scientific areas (a primary and secondary) of the proposal. For each area, enter the one-digit code and abbreviation (e.g., 1 CB).
2 CTR - Clinical and Translational Research 3 IDI - Infectious Diseases and Immunology 4 IE - Instrumentation and Engineering 5 MCB - Molecular and Cellular Biology 7 HIB - High-Throughput and Integrative Biology 8 BCB - Bioinformatics and Computational Biology For each area, enter the primary area first, followed by a semicolon, then add the secondary area (e.g., 1 CB; 7 NS).
The areas of science listed above are very broad and frequently overlap. Choose the two science areas most appropriate for your proposed project. The scientific areas are used solely as an aid to assign panel reviewers, who are chosen for their breadth of knowledge and expertise and will be able to review a broad range of applications.
Science area designations do not affect an application's funding potential, and application requirements and instructions are identical for all science areas. All applications are reviewed in the same time period, with the same review criteria, and compete for a single source of dedicated funds.
Note: The science area designations (two one-digit codes with abbreviation) must also be included at the beginning of the Research Strategy essay.
Type of Application (Field 8) : New Proposed Project (Field 12) : Start Date is September 1, 2027, and Ending Date is August 31, 2032 Estimated Project Funding (Field 15) : Total Federal Funds Requested (Field 15a) : $2,375,000 Total Non-Federal Funds (Field 15b) : $0 Total Federal & Non-Federal Funds (Field 15c) : $2,375,000 Estimated Program Income (Field 15d) : $0 Note: The total direct costs for the 5-year project period of the award is $2,375,000 and is entered in the "Total Federal Funds Requested" and "Total Federal & Non-Federal Funds" fields (as described above).
Applicable indirect costs will be determined at the time of award and should not be included in the budget request. A detailed budget and other budget forms are not required and will not be accepted. Funds may be used for personnel (including collaborators), supplies, equipment, subcontracts, data management and sharing costs, and other allowable costs.
SF424(R&R) Project/Performance Site Locations All instructions in the How to Apply - Application Guide must be followed. SF424(R&R) Other Project Information All instructions in the How to Apply - Application Guide must be followed. Bibliography & References Cited : DO NOT USE.
Provide essential reference citations in the essay. Facilities & Other Resources : Upload a brief statement (1-page maximum) of the facilities to be used for the conduct of the research. Other Attachments : Only attach Foreign Justification, if applicable.
SF424(R&R) Senior/Key Person Profile All instructions in the How to Apply - Application Guide must be followed. Profile – Project Director/Principal Investigator Field – Current and Pending Support : Attach a list of Current and Pending Support from all sources and effort devoted to each project in person months. Profile – Senior Key Person 1 : DO NOT USE.
Submit information only for PD/PI. Information on collaborators or other key personnel is not required but may be included in the Essay. Research and Related Senior/Key Person Profile (Expanded) - Additional Senior/Key Person Profiles(s) : DO NOT USE.
Only the PD/PI may serve as senior/key personnel. Research and Related Senior/Key Person Profile (Expanded) - Additional Biographical Sketch(es) : DO NOT USE. Only the PD/PI may submit a Biographical Sketch.
All instructions in the How to Apply - Application Guide must be followed. All instructions in the How to Apply - Application Guide must be followed. PHS 398 Cover Page Supplement All instructions in the How to Apply - Application Guide must be followed.
All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions: Specific Aims : DO NOT USE Research Strategy : The Research Strategy section should be structured as an essay that focuses on the goals of the New Innovator Award.
The essay should consider (1) the significance and potential impact of the project, (2) what makes the approaches exceptionally innovative, (3) how will risks and challenges be addressed, and (4) the applicant's qualifications for this award (without duplicating information in the biosketch). Presenting the proposed research as a series of specific aims is discouraged, and a detailed experimental plan should not be included.
Preliminary data are allowed but not required. The description of the scientific plan should be written at a level appropriate for reviewers who are broadly knowledgeable but may not be experts in the research area.
The essay should include the following sections in order with headings and within the page limit: Project science areas : Provide 1-digit code and abbreviation for primary and secondary science areas at the beginning of essay. See "Agency Routing Identifier" information above for codes and format.
Project Description : Describe the scientific challenge or opportunity that you propose to address, its importance, and how addressing this would have a major impact on a broad area of research relevant to NIH. Provide the scientific context by summarizing the current landscape of the field and how your research, if successful, would extend substantially beyond current boundaries. Describe the overall approach to be taken.
State prominently that to comply with the NOFO, a detailed experimental plan and extensive preliminary data are not being provided. However, the essay must be written so that reviewers have a clear sense of what is being proposed to be done and why and are convinced that the research will be performed in a robust and rigorous manner.
Innovativeness : State clearly and concisely what makes your project bold and unusually innovative in the context of what is currently state-of-the-art in the field. Since the approaches may be highly innovative, and hence risky, what will you do if these approaches are not successful? Investigator qualifications : Provide evidence to support your claim of innovativeness and creativity in your prior research.
For example, what personal qualities and experiences demonstrate your inclination to question paradigms and work with intellectual uncertainties, develop unique collaborations, integrate diverse sources of information, or develop novel approaches when new challenges or opportunities arise?
Suitability for the New Innovator Award : Explain why the planned research is uniquely suited to the New Innovator Award rather than a more "traditional" grant mechanism. Statement of research effort commitment : A statement must be included that, if chosen to receive an award, the applicant will commit a minimum of three person-months (25%) of their research effort to the project supported by the New Innovator Award.
Note: Any bibliographic citations provided must fit within the ten-page limit. To aid in the assessment of scientific rigor, inclusion of the most critical citations is encouraged. Figures and illustrations may be included but must also fit within the ten-page limit.
Letters of collaboration will not be accepted. Information on collaborators may be included in the Essay and their names and affiliations should be listed in the PHS Assignment Request Form in the section for individuals who should not review the application.
Applicants considering clinical trial research are strongly advised to discuss their research with the scientifically most relevant NIH Institutes or Centers (ICs) to ensure that such research would conform to the clinical trial research policies of those ICs. Funding of applications involving clinical trials is contingent upon conformance to the policies of the IC administering the award.
For a list of IC staff contacts, see links through the NIH Common Fund website . Progress Report Publication List : DO NOT USE. Multiple PD/PI Leadership Plan : DO NOT USE.
Consortium/Contractual Arrangements : DO NOT USE. Letters of Support : DO NOT USE. Letters of Support are not allowed.
Resource Sharing Plan : Individuals are required to comply with the instructions for the Resource Sharing Plans as provided in the How to Apply - Application Guide . For this NOFO, the Resource Sharing Plan will be expected as Just in Time information if an award is being considered.
All instructions in the How to Apply - Application Guide must be followed, with the following additional instructions: A Data Management and Sharing Plan (DMS Plan) is required for any NIH-funded or conducted research that will generate scientific data. Applicants must submit the DMS Plan at the time of application using the NIH DMS Plan Format Page . The DMS Plan must address the elements in the structured format.
Where the DMS Plan Format Page requires a "Yes or No" response, no additional narrative is allowed. Appendix: Only limited Appendix materials are allowed. Follow all instructions for the Appendix as described in the How to Apply - Application Guide .
No publications or other material, with the exception of blank questionnaires or blank surveys, may be included in the Appendix.
PHS Human Subjects and Clinical Trials Information When involving human subjects research, clinical research, and/or NIH-defined clinical trials (and when applicable, clinical trials research experience) follow all instructions for the PHS Human Subjects and Clinical Trials Information form in the How to Apply - Application Guide , with the following additional instructions: If you answered "Yes" to the question "Are Human Subjects Involved?"
on the R&R Other Project Information form, you must include at least one human subjects study record using the Study Record: PHS Human Subjects and Clinical Trials Information form or Delayed Onset Study record. Study Record: PHS Human Subjects and Clinical Trials Information All instructions in the How to Apply - Application Guide must be followed.
Note: Delayed onset does NOT apply to a study that can be described but will not start immediately (i.e., delayed start). All instructions in the How to Apply - Application Guide must be followed. PHS Assignment Request Form All instructions in the How to Apply - Application Guide must be followed.
Since all applications are received as "Office of the Director" applications and are reviewed by Special Emphasis Panels, applicants should not request assignment to a particular review panel (integrated review group) or awarding component (NIH Institute/Center).
Since letters of collaboration and biosketches of collaborators are not allowed, provide the names of collaborators and their institutional affiliations in the section for individuals who should not review the application. Also, if you wish to request that certain individuals not review your application, list their names, institutional affiliations, and the reasons why they should not serve as reviewers.
NIH will consider this request but is not obligated to accept it. 3. Unique Entity Identifier and System for Award Management (SAM) See Part 2.
Section III. 1 for information regarding the requirement for obtaining a unique entity identifier and for completing and maintaining active registrations in System for Award Management (SAM), NATO Commercial and Government Entity (NCAGE) Code (if applicable), eRA Commons, and Grants. gov 4.
Submission Dates and Times Part I. contains information about Key Dates and times. Applicants are encouraged to submit applications before the due date to ensure they have time to make any application corrections that might be necessary for successful submission.
When a submission date falls on a weekend or Federal holiday , the application deadline is automatically extended to the next business day. Organizations must submit applications to Grants. gov (the online portal to find and apply for grants across all Federal agencies).
Applicants must then complete the submission process by tracking the status of the application in the eRA Commons , NIH's electronic system for grants administration. NIH and Grants. gov systems check the application against many of the application instructions upon submission.
Errors must be corrected and a changed/corrected application must be submitted to Grants. gov on or before the application due date and time. If a Changed/Corrected application is submitted after the deadline, the application will be considered late.
Applications that miss the due date and time are subjected to the NIH Grants Policy Statement Section 2. 3. 9.
2 Electronically Submitted Applications . Applicants are responsible for viewing their application before the due date in the eRA Commons to ensure accurate and successful submission. Information on the submission process and a definition of on-time submission are provided in the How to Apply – Application Guide .
5. Intergovernmental Review (E. O.
12372) This initiative is not subject to intergovernmental review. All NIH awards are subject to the terms and conditions, cost principles, and other considerations described in the NIH Grants Policy Statement . Pre-award costs are allowable only as described in the NIH Grants Policy Statement Section 7.
9. 1 Selected Items of Cost . 7.
Other Submission Requirements and Information Applications must be submitted electronically following the instructions described in the How to Apply - Application Guide . Paper applications will not be accepted. Applicants must complete all required registrations before the application due date.
Section III. Eligibility Information contains information about registration. For assistance with your electronic application or for more information on the electronic submission process, visit How to Apply – Application Guide .
If you encounter a system issue beyond your control that threatens your ability to complete
According to the current listing, eligibility includes: New investigators proposing unusually innovative research. Specific eligibility criteria would be detailed in the full RFA RM 25-002 notice. Confirm the full requirements in the official notice before applying.
The current listing shows $475,000. Verify award ceilings, matching requirements, and allowable costs in the official notice.
National Institutes of Health (NIH) Director's New Innovator Award Program (DP2 Clinical Trial Optional) is funded by National Institutes of Health. Verify program details on the funder's official page before applying.
Start from the official opportunity page linked in this listing — it carries the sponsor's submission instructions.
PA-27-037 consolidates the Predoctoral to Postdoctoral Transition Award into a single parent announcement across 20 NIH components, with the next deadline December 8, 2026. The eligibility gate is not the science — it is a mandatory change of institution and mentor between the F99 and K00 phases.
Read articleA draft executive order would have put OMB Director Russell Vought on a commission with final say over NIH awards after peer review. Sen. Collins killed it by pointing at a provision Congress already passed. Here is what the episode teaches applicants about the December 11 cliff.
Read articlePA-27-034, PA-27-035 and PA-27-036 replace the institute-specific R25 announcements that research education programs have been built around for a decade. NCI, NIDA and NIGMS have already expired theirs early. Here is what the consolidation actually changes: an 8% indirect cost ceiling, a US-citizens-and-permanent-residents participant rule, a cooperative agreement variant that only exists on one of the three, and no clinical-trial-allowed companion anywhere.
Read article